Search
National societies
EHA pursues close collaboration with the national hematology societies to ensure that the professional hematology community in Europe is served in the best possible way.
Read moreAbstract submission
Abstract procedureThe official abstract submission is closed as of March 1, 2024 (23:59 CET).
Read moreEHA-SPH joint membership
Save up to €50 by becoming a joint member of EHA and the Sociedade Portuguesa de Hematologia. We've joined forces with the Sociedade Portuguesa de Hematologia (SPH) to offer a special joint membership deal during 2024.
Read moreYoungEHA Mentorship Mixer at EHA2024
Hosted by the YoungEHA Committee, the Mentorship Mixer is a pilot event for a potential EHA mentorship program.
Read moreEHA-SRH Joint membership
We are pleased to inform that EHA and the Societatea Română de Hematologie (SRH) have joined forces and are offering you the possibility of an EHA-SRH Joint Membership in 2023.
Read moreEHA-SPSHTM joint membership
Save up to €75 by becoming a joint member of EHA and the Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova.
Read moreEHA Guidelines by Topic
AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Bleeding and thrombosis
EHA Guidelines on management of antithrombotic treatments…
Access
Improving affordable and equal access to innovative therapies in hematology for patients across Europe is EHA’s overriding advocacy priority.
Read morePolicy & advocacy
At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.
Read moreEHA-KCS Hematology Tutorial
EHA is joining the Kazakhstan Cancer Society (KCS) to organize the EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies.
Read more